Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in a real world setting. Eighty-six Hungarian patients were included, 45 of whom received pomalid...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Pathology and Oncology Research |
| Subjects: | |
| Online Access: | https://www.por-journal.com/articles/10.3389/pore.2022.1610645/full |
| _version_ | 1797218151626178560 |
|---|---|
| author | Szilvia Lovas Nóra Obajed Al-Ali Gergely Varga Virág Szita Hussain Alizadeh Márk Plander Péter Rajnics Árpád Illés Zsuzsa Szemlaky Gábor Mikala László Váróczy |
| author_facet | Szilvia Lovas Nóra Obajed Al-Ali Gergely Varga Virág Szita Hussain Alizadeh Márk Plander Péter Rajnics Árpád Illés Zsuzsa Szemlaky Gábor Mikala László Váróczy |
| author_sort | Szilvia Lovas |
| collection | DOAJ |
| description | Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in a real world setting. Eighty-six Hungarian patients were included, 45 of whom received pomalidomide ± an alkylating agent, while in 38 of them pomalidomide was combined with a proteasome inhibitor. 56 patients (65%) showed any response to the treatment with 18 complete or very good partial remissions and 38 partial remissions. At a median duration of follow-up of 18.6 months, the median progression-free survival (PFS) was 9.03 months, while the median overall survival (OS) was 16.53 months in the whole cohort. Patients with early stage disease (R-ISS 1 and 2) had better survival results than those with stage 3 myeloma (p = 0.002). Neither the number of prior treatment lines, nor lenalidomide refractoriness had a significant impact on PFS. PFS was found similar between the cohort of patients with impaired renal function and the cohort without kidney involvement. During the study, eight mortal infections and two fatal bleeding complications occurred, however, mild hematologic and gastrointestinal toxicities were identified as the most frequent adverse events. The results of our investigations confirm that pomalidomide is an effective treatment option for relapsed/refractory MM, besides, the safety profile is satisfactory in subjects with both normal and impaired renal function. |
| first_indexed | 2024-04-24T12:13:12Z |
| format | Article |
| id | doaj.art-108b0d10eefe48f3bdd373b674f12ec2 |
| institution | Directory Open Access Journal |
| issn | 1532-2807 |
| language | English |
| last_indexed | 2024-04-24T12:13:12Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Pathology and Oncology Research |
| spelling | doaj.art-108b0d10eefe48f3bdd373b674f12ec22024-04-08T09:32:19ZengFrontiers Media S.A.Pathology and Oncology Research1532-28072022-10-012810.3389/pore.2022.16106451610645Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From HungarySzilvia Lovas0Nóra Obajed Al-Ali1Gergely Varga2Virág Szita3Hussain Alizadeh4Márk Plander5Péter Rajnics6Árpád Illés7Zsuzsa Szemlaky8Gábor Mikala9László Váróczy10Department of Hematology, Institute for Medicine, Faculty of Medicine, University of Debrecen, Debrecen, HungaryDepartment of Hematology, Institute for Medicine, Faculty of Medicine, University of Debrecen, Debrecen, HungaryDepartment of Internal Medicine and Hematology, Semmelweis University, Budapest, HungaryDepartment of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary1st Department of Internal Medicine, University of Pécs, Pécs, HungaryDepartment of Hematology, Markusovszky Teaching Hospital, Szombathely, HungaryDepartment of Hematology, Mór Kaposi Teaching Hospital, Kaposvár, HungaryDepartment of Hematology, Institute for Medicine, Faculty of Medicine, University of Debrecen, Debrecen, HungaryDepartment of Hematology and Stem Cell Transplantation, South-Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, HungaryDepartment of Hematology and Stem Cell Transplantation, South-Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, HungaryDepartment of Hematology, Institute for Medicine, Faculty of Medicine, University of Debrecen, Debrecen, HungaryPomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in a real world setting. Eighty-six Hungarian patients were included, 45 of whom received pomalidomide ± an alkylating agent, while in 38 of them pomalidomide was combined with a proteasome inhibitor. 56 patients (65%) showed any response to the treatment with 18 complete or very good partial remissions and 38 partial remissions. At a median duration of follow-up of 18.6 months, the median progression-free survival (PFS) was 9.03 months, while the median overall survival (OS) was 16.53 months in the whole cohort. Patients with early stage disease (R-ISS 1 and 2) had better survival results than those with stage 3 myeloma (p = 0.002). Neither the number of prior treatment lines, nor lenalidomide refractoriness had a significant impact on PFS. PFS was found similar between the cohort of patients with impaired renal function and the cohort without kidney involvement. During the study, eight mortal infections and two fatal bleeding complications occurred, however, mild hematologic and gastrointestinal toxicities were identified as the most frequent adverse events. The results of our investigations confirm that pomalidomide is an effective treatment option for relapsed/refractory MM, besides, the safety profile is satisfactory in subjects with both normal and impaired renal function.https://www.por-journal.com/articles/10.3389/pore.2022.1610645/fullsurvivaltoxicitymultiple myelomatreatment responsepomalidomide |
| spellingShingle | Szilvia Lovas Nóra Obajed Al-Ali Gergely Varga Virág Szita Hussain Alizadeh Márk Plander Péter Rajnics Árpád Illés Zsuzsa Szemlaky Gábor Mikala László Váróczy Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary Pathology and Oncology Research survival toxicity multiple myeloma treatment response pomalidomide |
| title | Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary |
| title_full | Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary |
| title_fullStr | Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary |
| title_full_unstemmed | Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary |
| title_short | Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary |
| title_sort | pomalidomide treatment in relapsed refractory multiple myeloma patients real world data from hungary |
| topic | survival toxicity multiple myeloma treatment response pomalidomide |
| url | https://www.por-journal.com/articles/10.3389/pore.2022.1610645/full |
| work_keys_str_mv | AT szilvialovas pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT noraobajedalali pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT gergelyvarga pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT viragszita pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT hussainalizadeh pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT markplander pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT peterrajnics pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT arpadilles pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT zsuzsaszemlaky pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT gabormikala pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT laszlovaroczy pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary |